Related Experiment Video
Updated: Jun 28, 2025
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.5K
Biomarker-oriented chemo-immunotherapy for advanced gastric cancer
Koji Kono1, Shotaro Nakajima2,3, Kosaku Mimura2,4
1Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, 960-1295, Japan. kojikono@fmu.ac.jp.
International Journal of Clinical Oncology
|April 22, 2024
Summary
Biomarker-driven therapies are advancing gastric cancer treatment. This review highlights key biomarkers like HER2, PD-L1, and Claudin18.2 for targeted anticancer drug development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Biomarker-oriented chemo-immunotherapy shows promise for anticancer drug development by enriching patient responders.
- Development of biomarker-driven therapeutics for gastric cancer has lagged compared to other cancers like colorectal and lung.
- Recent discoveries and clinical trials are advancing targeted therapies for gastric cancer.
Purpose of the Study:
- To review significant biomarkers in gastric cancer.
- To discuss the clinical significance of these biomarkers.
- To highlight associated targeted therapeutic agents.
Main Methods:
- Literature review of recent studies on gastric cancer biomarkers.
- Analysis of clinical trial data for biomarker-driven therapies.
- Focus on human epidermal growth factor receptor 2 (HER2), programmed death-ligand 1 (PD-L1), and Claudin18.2.
Main Results:
- HER2, PD-L1, and Claudin18.2 are key biomarkers in gastric cancer.
- These biomarkers have demonstrated clinical significance in patient stratification.
- Targeted agents associated with these biomarkers offer new treatment options.
Conclusions:
- Individualized, biomarker-oriented strategies are becoming viable for gastric cancer treatment.
- Targeted therapies based on HER2, PD-L1, and Claudin18.2 represent a promising frontier.
- Continued research in biomarker discovery and targeted agents is crucial for advancing gastric cancer care.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K